Specializing in Commercial Development, Marketing & Strategy for animal health pharmaceutical, biotechnology, nutrition and veterinary clients - Advisor for multiple animal health start-ups in the pharmaceutical and biological spaces - Advised financial sector clients looking to invest in or acquire companies in the pet and animal health sector - Provided commercial, marketing and strategy guidance for multinational animal health pharmaceutical and nutrition companies

Animal Health biotechnology start-up specializing in the development of vaccines and biologics for honey bees

Global Marketing Lead for Cargill Animal Nutrition & Health- Designed and stood up global marketing team for Cargill Animal Nutrition & Health with the integration of Diamond V and acquisition of Delacon- Lead a team of 25 with responsibilities spanning strategic marketing, global brand management, creative design, sales enablement, marketing communications, and digital/web/social capabilities- Lead strategic planning and organic growth drivers process annually for all key markets to determine Where to Play and How to Win- Built centralized resources and processes to support global function including global asset repository and regulatory review process; established internal system for resource and capability transfer to markets- Developed marketing capabilities and best practices including digital, product positioning & value proposition, customer journey, customer segmentation, and offering design

Leader of global team responsible for pipeline strategy, global brands’ lifecycle management and new market assessments for USD 1.75B business worldwide.- Strategic Planning: designed, implemented and executed on Species' Innovation Strategy to drive long-term growth and profitability for over one-third of global sales (Beef, Dairy, Equine, Small Ruminant)- Global Brand Management: managed all aspects of major brands and franchises (>$20MM annual sales) including go-to-market strategy, global launches, forecasting and lifecycle management- Investment Management: prioritized R&D assets and research studies for designated species efficiently to maximize return on pipeline investment- Mergers and Acquisitions: Provided strategic and financial analysis including go/no-go recommendations for acquisitions in both direct and complementary spaces which drove top-line growth and a more broad global presence - Corporate Structure and Reorganization: built and led global, diverse team of executives responsible for management of all species' therapeutic areas worldwide

Head of Regional species team (Ruminants, ~$500MM annual revenue) responsible for delivering on commercial commitments across multiple business sectors in 35 established and emerging markets.- Leadership: led team of Business Unit Directors from all major European Markets and Emerging Markets responsible for design, alignment and execution of regional species' strategies including product launches and franchise management- Marketing: led of team of Directors responsible for species' franchises including regional marketing and technical services. Responsibilities included branding, messaging, positioning and digital marketing platforms - Investment prioritization: managed prioritization of investment in pipeline and assets across all species to ensure increasing market share and growth in region within allocated R&D budget

Head of global strategic planning; responsible for execution of initiatives and delivery of long-term objectives.- Strategy: Created unified global strategy, rolled out on a regional basis, which included Embrex biodevice franchise as well as integration of major biological and pharmaceutical assets acquired from Synbiotics and Alpharma- Pricing: Developed and rolled out loyalty pricing program and discount program for key markets including the US, Brazil and China- Trade and Policy: External liaison to international trade groups; head of trade policy and governmental issue analysis for Global Poultry division

Manager of companion animal and equine biologicals and anti-infectives pipeline.- Go-to-market Strategy: late pipeline management of products including branding, pricing, messaging & positioning - Financial forecasting: forecasting and modeling for global pipeline products and acquisition targets- Lifecycle Management: identification, valuation and prioritization of value-add product enhancements including new label claims, packaging changes, delivery/administration technology and complementary offeringsLaunch Team Lead- Led twenty person team which developed look & feel, branding, messaging and positioning for global brand and US launch of EXCEDE Equine

Economic analyst for OPIC, the U.S. governmental branch which invests funds, guarantees loans and insures major corporate business ventures in the developing world.- Market and Trade Analysis- Economic Impact Evaluation

Analyst and consultant for a private agribusiness firm specializing in international trade, consulting, and financial services in the animal health and agricultural biotechnology sectors.- Agribusiness & Biotechnology Industry Analysis

C. Heller, C. Stem, H. Wamwayi, A. Grieve. Development of a filter paper-based ELISA for Rinderpest antibodies. The Veterinary Record (June 27, 1998).